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The calcium-sensing receptor (CaSR) is the principal regulator of the secretion of parathyroid hormone and
plays key roles in extracellular calcium (Ca2+o) homeostasis. It is also thought to participate in the development
of cancer, especially bony metastases of breast and prostate cancer. However, the expression of CaSR has not
been systematically analyzed in prostate cancer from patients with or without bony metastases. By comparing
human prostate cancer tissue sections in microarrays, we found that the CaSR was expressed in both normal
prostate and primary prostate cancer as assessed by immunohistochemistry (IHC). We used two methods to
analyze the expression level of CaSR. One was the pathological score read by a pathologist, the other was the
positivity% obtained from the Aperio positive pixel count algorithm. Both of the methods gave consistent results.
Metastatic prostate cancer tissue obtained from bone had higher CaSR expression than primary prostate cancer
(P <0.05). The expression of CaSR in primary prostate cancers of patients with metastases to tissues other than
bone was not different from that in primary prostate cancer of patients with or without bony metastases (P
>0.05). The expression of CaSR in cancer tissue was not associated with the stage or status of differentiation of
the cancer. These results suggest that CaSR may have a role in promoting bony metastasis of prostate cancer,
hence raising the possibility of reducing the risk of such metastases with CaSR-based therapeutics.
Keywords: calcium-sensing receptor; prostate; cancer; bone; metastasis
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Introduction
The calcium (Ca2+)-sensing receptor (CaSR) plays a

central role in calcium homeostasis by sensing small
changes in the level of extracellular calcium (Ca2+o) and
regulating parathyroid hormone (PTH) secretion and renal
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in breast cancer patients [22]. Liao et al. found that PC-3
prostate cancer cells (originally obtained from a bony
metastasis) have higher levels of CaSR mRNA than
LNCaP cells (obtained from a lymph node). Increasing the
extracellular calcium concentration stimulates growth of
PC-3 cells but not of LnCaP cells [23]. Knockdown of CaSR
expression reduces growth of PC-3 cells both in vitro and
in vivo in a murine model of prostate cancer metastasis [23].
However, a direct comparison of CaSR expression level in
the bony metastases with that in the primary cancers in
prostate is still lacking. Therefore, the relative levels of
CaSR expression in primary prostate cancers and in
metastases to bone and other sites as well as the associated
implications for the metastatic process are not clear.
In this study, we performed immunohistochemistry
(IHC) to detect CaSR expression in various benign and
malignant prostatic tissues on human prostate cancer tissue
microarrays. Our results identified a higher expression
level of CaSR in bony metastases of prostate cancer than
that in specimens of primary prostate cancer.
Materials and Methods
Fig 1. Examples of IHC staining of CaSR in tissue
microarrays. Four groups of tissues are shown: normal prostate
tissue, primary prostate cancers in patients with bony metastasis,
primary prostate cancers in patients without bony metastasis,
and prostate cancer from bone. (×40).

calcium excretion so as to normalize Ca2+o. Naturally
occurring mutations cause familial hypocalciuric
[1],
hypercalcemia
(FHH)
neonatal
severe
hyperparathyroidism (NSHPT) [2] and autosomal dominant
hypocalcemia with hypercalciuria (ADHH) [3]. The CaSR
was first cloned from bovine parathyroid glands [4] and
belongs to class C of the G protein-coupled receptors
(GPCR). CaSR also has been suggested to modulate
adipocyte function [5], carcinogenesis [6], insulin secretion
[7], mineralization of the bony matrix [8] and pathological
calcification [9], etc. Recently, much more attention has
been paid to possible roles of CaSR in various types of
cancer, including colon cancer [10, 11], breast cancer [12, 13],
prostate cancer [14, 15], ovarian cancer [16], Leydig cell
cancer [17], gastric cancer [18], insulinoma [19], and
glioblastoma [20].
In breast and prostate cancer, CaSR has been suggested
to participate in bony metastasis. It has been implicated in
a vicious cycle of bony metastases through its modulation
of parathyroid hormone related peptide (PTHrP) secretion
by cancer cells [21]. Mihai et al. found that most breast
cancer patients with a high expression of CaSR in
malignant tissue obtained from the breast had bony
metastases. They suggested that CaSR can serve as a
biomarker to predict the potential risk of bony metastasis

Tissue microarrays
Tissue arrays containing both prostate cancer tissue and
normal prostate tissue (PR807 and PR955) were purchased
from the Biomax Company (Rockville, MD
www.biomax.us). The tissue samples, including (1)
normal prostate tissue, (2) primary prostate cancer tissue
in patients with or without bony metastases, (3) prostate
cancer tissue from bony metastases, and (4) prostate
cancer tissue from abdominal wall metastases in two tissue
microarrays, which were combined to enlarge the sample
size. Altogether, there were 24 samples of normal prostate
tissue, 108 samples of primary prostate cancer tissue (i.e.,
obtained from the prostate gland), and 4 samples of
prostate cancer tissue obtained from bony metastases
(Table 1). Among the 108 prostate cancer patients
represented by the two arrays in which cancer tissue was
obtained from the prostate, 12 of them had coexistent bony
metastases while 96 of them did not. Tissue specimens
were not available from the bony metastases in these 12
patients.
Immunohistochemistry (IHC)
The slides were first deparaffinized by heating at 60°C
for 2 hours. Then they were boiled in 10 mM citrate
sodium solution (pH 6.0) for 10 min for antigen retrieval,
followed by incubation in 3% H2O2 for 5-10 min to block
endogenous peroxidase. After blocking in normal goat
serum for 20 min, the slides were incubated with rabbit
polyclonal anti-CaSR antibody raised against a synthetic
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Fig 2. Pathological score and positivity% for CaSR expression in each group, as quantitated in
prostate tissue microarrays. A: Comparison of pathological scores of normal prostate tissue, primary
prostate cancer tissue, and prostate cancer tissue from bone. B: Comparison of pathological scores of
primary prostate cancer tissue from patients with bony metastasis and primary prostate cancer tissue from
patients without bony metastasis. C: Comparison of positivity% of normal prostate tissue, primary prostate
cancer tissue, and prostate cancer tissue from bone. D: Comparison of positivity% of primary prostate
cancer tissue from patients with bony metastasis and primary prostate cancer tissue from patients without
bony metastasis.

peptide whose sequence is within the first third of the
receptor’s N-terminal extracellular domain (Sigma, St.
Louis, MO) at 4°C overnight. The specificity of the
antibody was documented by negative control IHC
(Supplemental Figure 1) (i.e., by omitting the first
antibody) and the western blot (Supplemental Figure 2)
asdescribed in Results. Biotinylated anti-rabbit antibody
was used as secondary antibody. Staining was visualized
using 3, 3'-Diaminobenzidine (DAB) tetrahydrochloride,
and slides were counterstained with hematoxylin.
Analysis of IHC staining
The tissue microarrays were read by a pathologist (B.L.)
blinded to the identity of the tissue sections. The staining

intensity in any given tissue section was given a grade of
1, 2 or 3. A higher grade indicates a higher intensity of
staining. The area ratio stands for the percentage of the
area stained for CaSR over the total epithelial cellular area.
The final pathological score was obtained by multiplying
the intensity grade by the area ratio. The tissue microarray
was also scanned using a Hamamatsu/Olympus
Nanozoomer 2.0HT whole slide image scanner
(Hamamatsu Photonics K.K., Hamamatsu, SZK). The
whole slide image was viewed in the Aperio ImageScope
program (Vista, CA) and analyzed with the Aperio
positive pixel count algorithm similar to methods
previously described [24]. The default hue (brown) for the
positive pixel count algorithm was used. The positivity
(number of positive pixels over total number of pixels) of
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each sample was obtained for statistical analysis.
Western Blot
Cell lysates of cells were extracted and loaded onto an
SDS-PAGE gel. After electrophoresis, equal amounts of
protein from each sample were transferred to a
nitrocellulose membrane. Then the membrane was
blocked, incubated with Sigma anti-CaSR antibody and
then secondary antibody sequentially. The protein bands
were
then
visualized
using
an
enhanced
chemiluminescence reaction system (Bio Rad, Hercules,
CA).
Statistical analysis
Statistical analyses of differences between groups were
carried out by R software (R Development Core Team)
using Student’s t test, the Wilcox test, or the KolmogorovSmirnov test according to whether the samples were
normally distributed or not. If both groups were normally
distributed with the same variance, Student’s t test was
used. If neither of the two groups had a normal
distribution, the Wilcoxon test was used. If one group was
normally distributed but the other was not, the
Kolmogorov-Smirnov test was used. A value of P < 0.05
was taken as indicating a statistically significant
difference. All of the tests are two-sided. Pearson’s
correlation was used to analyze the correlation among
groups. P < 0.05 was taken to indicate a statistically
significant correlation.
Results
Patient information
Figure 1 and Supplemental Figure 3 shows normal
prostate tissue with a regular glandular structure. CaSR
is expressed both in the cell membrane and in the
cytoplasm of all of the epithelial cells. Primary prostate
cancer tissue also expresses CaSR in all of the cancer cells

with the same cellular localization, regardless of bony
metastases or not. Prostate cancer tissue obtained from
bone does not typically have a glandular structure, and the
cancer cells cluster together, expressing much more CaSR
than in prostate cancer sections obtained from the prostate
or from non-bony metastases, as shown by the deep brown
color in the bony metastases. Two cases of prostate cancer
tissues obtained from the abdominal wall also did not have
a glandular structure but show less staining than the cancer
tissues obtained from bone.
CaSR expression levels in patient tissues were analyzed
using two complementary methods. As shown in Table 1,
the median pathological score of normal prostate tissue
was 180 with a 25th percentile of 95 and 75th percentile of
214, and the median pathological score of all prostate
cancer tissue samples obtained from prostate was 190 with
a 25th percentile of 115 and 75th percentile of 240. All of
the 4 prostate cancer tissues obtained from bone had the
same pathological score of 300 (i.e., all had intensity
grades of 3 with 100% of the cells staining positive for
CaSR). Two cases of prostate cancer tissues obtained from
the abdominal wall had a score of 120.
The Aperio positive pixel count algorithm was applied
to measure the areas and intensities in IHC results [24, 25].
The positivity%, which describes the number of positive
pixels over the total number of pixels of each sample, was
used, in addition to the use of the pathological score, to
analyze the expression level of CaSR. The semiquantitative values obtained by this method are
summarized in Table 2 for detailed comparison. The
median positivity% of normal prostate tissue was 0.07
with a 25th percentile of 0.03 and 75th percentile of 0.14,
and the median positivity% of all prostate cancer tissue
samples obtained from prostate was 0.07 with a 25th
percentile of 0.03 and 75th percentile of 0.16. All of the 4
prostate cancer tissues obtained from bone had a
positivity% of around 0.39. Therefore the use of these two
different methods yielded quite consistent results, showing
a significant correlation by linear regression between
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Fig 3. Relationship between pathological score and positivity% for CaSR expression and cancer progression stage, Gleason
score, and PSA concentration in blood. A: Relationship between pathological score of CaSR expression in primary prostate cancers
and cancer stages. B: Relationship between pathological score of CaSR expression in primary prostate cancers and Gleason Score. C:
Relationship between pathological score of CaSR expression in primary prostate cancers and PSA concentration. D: Relationship
between positivity% of CaSR expression in primary prostate cancers and cancer stages. E: Relationship between positivity% of CaSR
expression in primary prostate cancers and Gleason Score. F: Relationship between positivity% of CaSR expression in primary prostate
cancers and PSA concentration.

pathological score and image analysis (Supplemental
Figure 4).
Statistical analysis of the pathological scores showed
that there was no difference in CaSR expression between
the normal prostate tissues and the primary prostate cancer
tissues (Fig. 2A) (P = 0.65). There were only 4 samples of
prostate cancer tissue metastatic to bone, and
consequently, the Kolmogorov-Smirnov test was used,
since it can be employed with small sample sizes. The
metastatic prostate cancer tissues obtained from bone have
higher CaSR expression than the prostate cancer
specimens obtained from prostate (P = 0.001) or the
normal prostate tissue (P = 0.004). Among the 108
samples of prostate cancer obtained from prostate, 12
samples were from patients having bony metastasis (tissue
from the bony metastases of these patients were not
available), and these had the same CaSR expression in the
primary prostate cancer specimens as that in the 96
samples from primary prostate cancer of patients having
no bony metastases (P = 0.67). (Figure 2B)
The positivity% results are shown in Figure 2 C and D.

The conclusions are the same. There was no difference in
CaSR expression between the normal prostate tissues and
the primary prostate cancer tissues (P = 0.97). The
metastatic prostate cancer tissues obtained from bone have
higher CaSR expression than the prostate cancer
specimens obtained from prostate (P = 0.003) or the
normal prostate tissue (P = 0.003). Samples from primary
prostate cancer tissue of patients having bony metastasis
had the same CaSR expression as the primary prostate
cancer samples from patients having no bony metastases
(P = 0.07).
Correlation of CaSR expression with cancer stage
The tissue array included 29 cases of stage 2 cancer, 44
cases of stage 3 cancer, and 33 cases of stage 4 cancer. The
scatter plot in Figure 3A shows that there is no correlation
between the pathological score for the CaSR and stage of
the cancer (R2 = 0.011, P = 0.54). The data on the stages
of the patient’s cancers are shown in Supplemental Table
1. The positivity% results also showed that there is
likewise no correlation (R2 = 0.007, P = 0.41) as in Figure
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3 D.
Correlation of CaSR expression with Gleason score
Cancers with a higher Gleason score are more
aggressive and have a worse prognosis. The scatter plot in
Figure 3B shows that there is no correlation between the
pathological score for CaSR expression and the Gleason
score (R2 = 0.003, P = 0.08). Information about the patients
on whom a Gleason score was available is shown in
Supplemental Table 2. There is also no correlation
between Gleason score and positivity% (R2 = 0.009, P =
0.31) as shown in Figure 3 E.
Correlation between CaSR expression and prostate
specific antigen (PSA) concentration
PSA, secreted by the epithelial cells of the prostate
gland, is often elevated in the presence of prostate cancer
or other prostate disorders. The normal PSA levels should
be less than 4 ng/mL. The scatter plot in Figure 3C shows
that there is no correlation between the pathological score
for CaSR expression and the PSA concentration in blood
(R2 = 0.013, P = 0.07). Information about the patients in
whom PSA values were available is shown in
Supplemental Table 3. There is also no correlation
between PSA and positivity% (R2 = 0.075, P = 0.05) as
shown in Figure 3 F.
Discussion
In this study, higher expression level of CaSR were
found to be associated with the metastatic prostate cancer
tissues obtained from bone rather than primary prostate
cancer tissues or normal prostate tissues, while no
significant difference in CaSR expression between normal
prostate tissue and primary prostate cancer tissue was
observed. The metastatic prostate cancer tissues studied
here that were obtained from bone have higher CaSR
expression than primary prostate cancer tissues. For the
second tissue microarray (designated PR955 by the
supplier), most of the tissues were obtained from prostate.
Some were obtained from metastatic sites: 6 from bone
and 2 from the abdominal wall. The samples of prostate
cancer obtained from bone in these arrays are very scarce
and fragile. Sections from two such bony metastases were
damaged. Therefore, only four were available for
statistical comparison with the staining from the other
tissues due to limitations of patient sample availability.
However, these four prostate cancer tissues obtained from
bone all showed the highest level of CaSR expression
among the tissues studied here, as reflected by the largest
possible pathological score of 300 for each specimen. 2
metastases from the abdominal wall both had scores of
only 120. This may suggest that high expression of CaSR

in the cancer tissue from bone is a consequence of their
localization in the bony environment, e.g., expression of
the CaSR may be upregulated by factors in the bony
microenvironment (see below). It is also possible that bone
selects for metastatic cells with high CaSR expression and
resultant increased potential to metastasize to bone
because bone is a “fertile field” [26] for them when they
express a high level of CaSR.
Importance of bone environment
Bone is a favored metastatic site for some cancer cells
. These metastatic sites are characterized by high rates
of bone turnover [28], with continuous breakdown of bone
by osteoclasts, followed by replacement of the missing
bone by osteoblasts. In some active lacunae where bone
resorption is taking place, the extracellular calcium level
can reach as high as 8-40 mmol/L [29]. The high calcium
concentration within this microenvironment could induce
the expression of the CaSR in cancer cells. High
concentrations of calcium and calcimimetics (i.e.,
allosteric CaSR activators) have, in fact, been shown to
upregulate expression of the CaSR in normal tissues, such
as parathyroid gland [30, 31]. Elevated extracellular calcium
concentrations stimulate parathyroid hormone related
peptide (PTHrP) production by prostate cancer cell lines
[32], which could increase bone resorption near bony
metastases of prostate cancer [33], thereby producing a
favorable environment for tumor growth and providing a
growth advantage for metastatic cancer cells having high
CaSR expression.
[27]

There is abundant literature addressing possible targets
for the treatment of prostate cancer [34, 35]. The seed and
soil theory is a popular one [36]. Cancer cells are regarded
as the seeds and the bony environment as the soil. Some
believe that the therapeutic target should be the seed. From
the point of view of our study, treatments targeting both
the seed (e.g., prostate cancer cells with high CaSR
expression) and soil (i.e., high local levels of Ca2+o in
bone) could be a better therapeutic direction in the clinic.
That is, a therapeutic approach combining inhibition of
bone resorption using a bisphosphonate [37], for example,
and suppression of CaSR activity with a calcilytic, e.g., a
negative allosteric modulator of the receptor [38]. While
such a combined approach has not been reported to our
knowledge, decreasing the level of expression of the CaSR
in PC-3 cells in a murine model of prostate cancer
metastasis to bone, reduced the metastatic burden in bone
[23].
Comparison with other studies
CaSR is considered to be an important factor in bony
metastases of some types of cancer. Breast cancer tissues
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from patients with bony metastases have higher expression
of CaSR than that of breast cancer from patients without
bony metastases. In our study, we didn’t see any
differences between CaSR expression in the primary
prostate cancers of patients with bony metastases and that
in the primary prostate cancers that had not metastasized
to bone. This might be due to the CaSR having different
functions in different types of cancer [39, 40]. Huang et al.
demonstrated that CaSR expression was significantly
higher in more tumorigenic prostate cancer cell lines and
in prostate cancer tissue specimens than in the normal
prostate cells [41]. However, this study did not use IHC to
detect the expression of CaSR protein in situ, but extracted
the protein from the normal tissue and cancer tissue then
performed western blot analysis. The number of tissue
specimens examined was also small.
Adams, et al. reported that hematopoietic stem cells
engraft in bone, at least in part, because of CaSR.
Hematopoietic stem cells from CaSR-/- mice exhibited
diminished adhesion to extracellular matrix proteins, even
though they were normal in their capacities to
differentiate, migrate and home to bone [42]. Therefore, if,
as we have suggested, CaSR expression increases after
prostate cancer cells arrive at bone, this increased CaSR
could potentially enhance the capacity of cancer cells to
localize in the bone by a similar mechanism(s).

This work was supported in part by National Institutes
of Health Grants GM081749 to JJY and a predoctoral
fellowship to JF from the Brain and Behavior Program at
Georgia State University. We thank Dr. Zhiren Liu for his
valuable advice, Chen Zhang for help in preparation of this
manuscript, Dr. Xue Wang for statistical analysis and
other members of the Yang group for helpful suggestions.
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Supplements

Suppl. Table 1. Pathological tumor (T) stage and positivity% for expression of CaSR in primary prostate cancer
tissues of patients with different stages of prostate cancer in array PR955
T Stage

Cases (N)

Pathological Score (%)
(intensity multiplied by area)
Median (25th, 75th percentiles)

Positivity (%)
Median
(25th, 75th percentiles)

2

29

180 (85,200)

0.06 (0.03,0.13)

3

44

190 (158,255)

0.06 (0.03,0.14)

4

33

180 (160,200)

0.08 (0.05,0.16)

The correlation P value for stage and pathological score is 0.54. The correlation P value for stage and positivity is 0.41.

Suppl. Table 2. Pathological scores and positivity% for expression of CaSR in primary prostate cancer tissues of
patients with different Gleason scores in array PR955
Gleason
score

Cases (N)

Pathological Score (%)
(intensity multiplied by area)
Median(25th, 75th percentiles)

Positivity (%)
Median
(25 , 75th percentiles)
th

4

1

200

0.26

5

1

170

0.25

6

12

175 (89,221)

0.09 (0.04,0.23)

7

34

195 (160,255)

0.08 (0.04,0.14)

8

16

190 (93,214)

0.10 (0.02,0.17)

9

32

185 (150,200)

0.05 (0.03,0.10)

10

11

180 (145,200)

0.15 (0.04,0.24)

The correlation P value for Gleason score and pathological score is 0.08. The correlation P value for Gleason score and
positivity is 0.31.

Suppl. Table 3. Pathological scores and positivity% for expression of CaSR in primary prostate cancer tissues of
patients with different PSA concentrations in array PR955
PSA(ng/mL)

Cases (N)

Pathological Score (%)
(intensity multiplied by area)
Median (25th, 75th percentiles)

Positivity (%)
Median
(25th, 75th percentiles)

0-4

5

160 (160,200)

0.02 (0.02,0.03)

4-10

9

200 (160,200)

0.03 (0.02,0.04)

10-20

20

185 (120,200)

0.06 (0.04,0.14)

20-40

13

255 (190,285)

0.12 (0.08,0.16)

>40

10

198 (190,253)

0.10 (0.03,0.12)

The correlation P value for PSA and pathological score is 0.07. The correlation P value for PSA and positivity is 0.05.
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Suppl. Figure 1. IHC staining of CaSR in prostate tissue with
Sigma anti-CaSR antibody (right) and negative control (left).
(×10)

Suppl. Figure 3. IHC staining of CaSR in prostate tissue
microarray PR955. Normal prostate tissue: H1-H11 and G9-G12
Primary prostate cancer: A1-A12, B1-B12, C1-C12, D1-D12, E1E12, and F1-F12. Prostate cancer from bone: G3-G8 (G5 and G6
were damaged). Prostate cancer from abdominal wall: G1-G2. (×4)

Suppl. Figure 4. Correlation between pathological score and
positivity%. (R2 = 0.35, P = 0.001)

Suppl. Figure 2. Western Blot of CaSR expression in
prostate cancer cell line, PC-3 cells, using Sigma antiCaSR antibody. GAPDH was detected as a loading control.
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